MarketBeat | Real-Time Financial News and Analysis

Open Main Menu Open Sidebar

bluebird bio Company Profile (NASDAQ:BLUE)

Consensus Ratings for bluebird bio (NASDAQ:BLUE) (?)
Ratings Breakdown: 5 Hold Rating(s), 12 Buy Rating(s)
Consensus Rating:Buy (Score: 2.71)
Consensus Price Target: $99.53 (150.62% upside)

Analysts' Ratings History for bluebird bio (NASDAQ:BLUE)
Show:
DateFirmActionRatingPrice TargetActions
6/13/2016Leerink SwannReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/2/2016Cantor FitzgeraldInitiated CoverageHold$42.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/11/2016Piper JaffrayReiterated RatingBuy$117.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/10/2016Janney Montgomery ScottReiterated RatingBuy$91.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/7/2016Jefferies GroupReiterated RatingBuy$84.00 -> $80.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/7/2016BTIG ResearchReiterated RatingBuy$72.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/5/2016Wells FargoReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/5/2016WedbushReiterated RatingOutperform$117.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
4/23/2016Goldman SachsReiterated RatingNeutral$149.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
4/20/2016Maxim GroupReiterated RatingBuy$105.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
2/23/2016Roth CapitalReiterated RatingNeutral$62.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
12/7/2015JPMorgan Chase & Co.DowngradeBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
12/7/2015Bank of AmericaDowngradeBuy -> Neutral$149.00 -> $102.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
12/7/2015Morgan StanleyDowngradeOverweight -> Equal Weight$143.00 -> $69.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
11/16/2015Cowen and CompanyReiterated RatingOutperformView Rating Details  Tweet This Rating  Share This Rating on StockTwits
11/5/2015OppenheimerReiterated RatingOutperform$162.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
9/18/2015BMO Capital MarketsInitiated CoverageBuy$14.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/15/2015SunTrustReiterated RatingBuy$205.00 -> $230.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 6/29/2014 forward)
Earnings History for bluebird bio (NASDAQ:BLUE)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallActions
8/4/2016        
5/4/2016Q1($1.23)($1.52)$4.50 million$1.50 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/24/2016Q4($1.11)($1.29)$3.21 million$1.47 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/6/2015Q215($0.78)($1.57)$8.60 million$4.94 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/6/2015Q115($0.61)($0.76)$6.20 million$6.30 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/25/2015Q414($0.57)($0.67)$6.20 million$6.30 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/12/2014Q314($0.50)($0.61)$6.20 million$6.40 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/12/2014Q214($0.45)($0.06)$6.15 million$6.30 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/13/2014Q114($0.32)($0.44)$6.23 million$6.30 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/5/2014($0.31)($0.34)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/12/2013Q3($0.25)($0.26)$5.59 million$6.39 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/8/2013Q213($0.35)($2.13)$4.85 million$6.30 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2011 forward)
Earnings Estimates for bluebird bio (NASDAQ:BLUE)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 201610($1.38)($0.92)($1.21)
Q2 201610($1.56)($0.99)($1.36)
Q3 201610($1.61)($1.12)($1.41)
Q4 201610($1.67)($1.29)($1.48)
Q1 20171($1.68)($1.68)($1.68)
Q2 20171($1.75)($1.75)($1.75)
Q3 20171($1.83)($1.83)($1.83)
(Data provided by Zacks Investment Research)
Dividend History for bluebird bio (NASDAQ:BLUE)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trading History for bluebird bio (NASDAQ:BLUE)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionActions
6/16/2016Philip D GregoryInsiderSell2,931$39.52$115,833.12View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/15/2016David DavidsonInsiderSell1,000$40.11$40,110.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/16/2016David DavidsonInsiderSell1,000$38.73$38,730.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/15/2016David DavidsonInsiderSell1,000$49.63$49,630.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/15/2016David DavidsonInsiderSell1,000$46.13$46,130.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/16/2016David DavidsoninsiderSell1,000$45.18$45,180.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/15/2016David DavidsoninsiderSell1,000$44.39$44,390.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/15/2015David DavidsoninsiderSell1,000$58.55$58,550.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/8/2015Nick LeschlyCEOBuy9,682$51.75$501,043.50View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/16/2015David DavidsoninsiderSell2,000$70.99$141,980.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/10/2015Jeffrey T. WalshCOOSell11,000$74.60$820,600.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/15/2015David DavidsoninsiderSell2,000$79.70$159,400.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/12/2015Jeffrey T. WalshCOOSell11,000$88.06$968,660.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/9/2015Jason ColeSVPSell5,000$86.91$434,550.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/5/2015Daniel LynchDirectorSell3,000$100.41$301,230.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/17/2015Daniel LynchDirectorSell1,500$140.06$210,090.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/15/2015David DavidsoninsiderSell2,000$129.98$259,960.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/10/2015Jeffrey T. WalshCOOSell11,000$130.02$1,430,220.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/9/2015Jason ColeSVPSell2,000$136.56$273,120.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/8/2015Daniel LynchDirectorSell7,000$132.75$929,250.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/8/2015Nick LeschlyCEOSell125,000$135.24$16,905,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/1/2015James MandellDirectorSell1,500$125.96$188,940.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/20/2015Eric SullivanInsiderSell1,126$163.36$183,943.36View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/15/2015David DavidsonInsiderSell2,000$165.96$331,920.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/10/2015Jeffrey T WalshCOOSell11,000$158.63$1,744,930.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/9/2015Jason ColeSVPSell5,000$158.19$790,950.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/15/2015David DavidsonInsiderSell2,000$183.34$366,680.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/10/2015Jeffrey T WalshCOOSell11,000$179.70$1,976,700.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/1/2015Mitchell H FinerInsiderSell15,000$190.25$2,853,750.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/20/2015Mitchell H FinerInsiderSell15,000$126.03$1,890,450.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/15/2015David DavidsonInsiderSell2,000$130.18$260,360.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/10/2015Jeffrey T WalshCOOSell21,000$126.21$2,650,410.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/2/2015Eric SullivanInsiderSell2,998$117.81$353,194.38View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/10/2015Jeffrey T WalshCOOSell10,500$110.06$1,155,630.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/2/2015David DavidsonInsiderSell4,000$94.84$379,360.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/12/2015Jeffrey T WalshCOOSell10,500$103.57$1,087,485.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/2/2015David DavidsonInsiderSell4,000$90.01$360,040.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/19/2014John MaraganoreDirectorBuy2,352$85.00$199,920.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/10/2014Jeffrey T WalshCOOSell43,500$78.06$3,395,610.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/8/2014David DavidsonInsiderSell15,000$46.10$691,500.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/3/2014David DavidsonInsiderSell3,000$41.65$124,950.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/1/2014Mitchell H FinerInsiderSell18,000$39.70$714,600.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/1/2014Nick LeschlyCEOSell2,417$39.70$95,954.90View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/3/2014David DavidsonInsiderSell3,000$41.68$125,040.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/3/2014Nick LeschlyCEOSell25,000$41.68$1,042,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/24/2014Nick LeschlyCEOSell33,900$40.22$1,363,458.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/10/2014Jeffrey T WalshCOOSell7,500$33.16$248,700.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/9/2014Steven GillisDirectorSell115,000$35.25$4,053,750.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/8/2014Mitchell H FinerInsiderSell34,518$33.52$1,157,043.36View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/7/2014Steven GillisDirectorSell57,435$35.43$2,034,922.05View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/2/2014Steven GillisDirectorSell91,165$35.28$3,216,301.20View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/1/2014David DavidsonInsiderSell3,000$34.55$103,650.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/1/2014Nick LeschlyCEOSell8,000$34.55$276,400.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/12/2014Robert I TepperDirectorSell125,000$36.54$4,567,500.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/10/2014Jeffrey T WalshCOOSell7,500$37.02$277,650.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/2/2014David DavidsonInsiderSell3,000$38.00$114,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/2/2014Nick LeschlyCEOSell10,300$38.45$396,035.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/11/2014Jeffrey T WalshCOOSell7,500$34.26$256,950.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/1/2014David DavidsonInsiderSell3,000$33.62$100,860.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/1/2014Nick LeschlyCEOSell8,000$33.62$268,960.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/14/2014John MaraganoreDirectorBuy2,941$34.00$99,994.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/10/2014Jeffrey T WalshCOOSell7,500$33.20$249,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/3/2014Nick LeschlyCEOSell22,283$39.86$888,200.38View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/1/2014David DavidsonInsiderSell3,000$39.55$118,650.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/20/2014Nick LeschlyCEOSell17,075$40.06$684,024.50View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/16/2014Jeffrey T WalshCOOSell1,500$39.86$59,790.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/16/2014Mitchell H FinerInsiderSell10,000$39.84$398,400.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/16/2014Nick LeschlyCEOSell42,925$40.02$1,717,858.50View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/10/2014Jeffrey T WalshCOOSell6,000$24.23$145,380.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/2/2014Mitchell H FinerInsiderSell8,000$22.21$177,680.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/2/2014Nick LeschlyCEOSell5,000$22.21$111,050.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/14/2014Jeffrey WalshCOOSell1,500$20.03$30,045.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/12/2014Jeffrey WalshCOOSell4,500$18.93$85,185.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/1/2014David DavidsonInsiderSell4,000$19.85$79,400.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/1/2014Nick LeschlyCEOSell5,000$20.07$100,350.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/10/2014Jeffrey WalshCOOSell6,000$21.29$127,740.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/22/2014Linda BainVPSell2,500$25.11$62,775.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/17/2014Robert TepperDirectorSell307,000$22.43$6,886,010.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/16/2014Mitchell FinerInsiderSell10,000$23.52$235,200.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/14/2014Robert TepperDirectorSell340,000$21.90$7,446,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/10/2014Jeffrey WalshCOOSell6,000$21.98$131,880.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/3/2014David DavidsonInsiderSell15,000$20.88$313,200.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/3/2014Linda BainVPSell5,000$20.89$104,450.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
(Data available from 1/1/2013 forward)
Latest Headlines for bluebird bio (NASDAQ:BLUE)
DateHeadline
06/29/16 11:11 AMbluebird bio, Inc. (NASDAQ:BLUE): Taking a look at the Consensus Estimates from Analysts - Telanagana Press
06/29/16 07:24 AMThese 3 Biotechs Are Down More Than 36% This Year, and They're Bargains -
06/28/16 08:11 PMRevenue Estimates for Brokers: bluebird bio, Inc. (NASDAQ:BLUE) - News Oracle
06/28/16 08:11 PMBTIG Weighs In on bluebird bio, Inc (BLUE) Following Meeting With Management - Smarter Analyst
06/28/16 08:11 PMbluebird bio Inc. (BLUE) Jumps 8.3% on June 28 - Equities.com
06/28/16 07:20 AMCovering the Bases on bluebird bio, Inc. (NASDAQ:BLUE): Where is the Stock Going? - Press Telegraph
06/27/16 02:32 PMNext Weeks Broker Price Targets For Bluebird Bio, Inc. (NASDAQ:BLUE) - Fiscal Standard
06/27/16 02:32 PMBiotechnology Equities at a Glance -- MannKind, bluebird bio, OncoGenex Pharma, and Hevat Biologics - PR Newswire (press release)
06/26/16 02:44 PMStrong Sell Calls Recommendations For bluebird bio, Inc. (NASDAQ:BLUE) At 0 - Investor Newswire
06/26/16 02:44 PMStock Performance Focus on: bluebird bio, Inc. (NASDAQ:BLUE) - Press Telegraph
06/26/16 02:44 PMAnalyst's Noticeable Buzzers: bluebird bio, Inc. (NASDAQ:BLUE) , Genocea Biosciences, Inc. (NASDAQ:GNCA) - Street Updates
06/26/16 08:05 AMbluebird bio : Diana Colleluori at Bluebird Bio to Present at GTCbio’s Cell & Gene Therapy Conference
06/22/16 02:43 AMBlue Financial Communication SpA :BLUE-IT: Earnings Analysis: 2015 By the Numbers : June 22, 2016 -
06/21/16 02:47 PMBrokers Issue Average Price Target Of 95.00 On Bluebird Bio, Inc. (NASDAQ:BLUE) - Fiscal Standard
06/21/16 07:37 AMbluebird bio, Inc. Stock Momentum Hits Weakness - CML News
06/20/16 01:06 PMETF’s with exposure to bluebird bio, Inc. : June 20, 2016 -
06/16/16 08:13 PMWill bluebird bio, Inc. (NASDAQ:BLUE) Surprise This Quarter? - Investor Newswire
06/16/16 02:51 PMPre-Market Investor's Alert: bluebird bio Inc (NASDAQ:BLUE), QLogic Corporation (NASDAQ:QLGC) - iStreetWire
06/13/16 03:06 PMAnalysts Offer Insights on Healthcare Companies: bluebird bio Inc (NASDAQ: BLUE), Cidara Therapeutics Inc ... - Markets.co
06/13/16 07:20 AMbluebird bio, Inc. breached its 50 day moving average in a Bearish Manner : BLUE-US : June 13, 2016 -
06/11/16 11:01 AMAnalyst's Valuable Buzzers: Sanofi (NYSE:SNY) , bluebird bio, Inc. (NASDAQ:BLUE) - Street Updates
06/10/16 08:46 PMWhy Global Blood Therapeutics Inc. Skyrocketed and bluebird bio Inc. Sank Today - Motley Fool
06/10/16 02:54 PMWhy Global Blood Therapeutics Inc. Skyrocketed and bluebird bio Inc. Sank Today - The motley Fool (blog)
06/10/16 12:37 PMWhy Global Blood Therapeutics Inc. Skyrocketed and bluebird bio Inc. Sank Today -
06/10/16 12:08 PMSickle-Cell Disease Success Drives Up Global Blood Stock, Slams Bluebird -
06/10/16 11:22 AMLonza inks commercial manufacturing pact for Bluebird Bio's drugs - Business Standard
06/09/16 02:54 PMCantor Fitzgerald Initiates Coverage on bluebird bio Inc to Hold - Trade Calls
06/09/16 11:47 AMBRIEF-Bluebird Bio says co, Lonza Houston enter into manufacturing agreement - Reuters
06/08/16 11:22 AMbluebird bio Inc. (BLUE) Jumps 6.16% on June 06 - Equities.com
06/07/16 11:05 AMInvestors Focused Stocks: CytRx Corporation (NASDAQ:CYTR) , bluebird bio, Inc. (NASDAQ:BLUE) - Street Updates
06/06/16 08:17 PMBluebird Bio (BLUE) Is Today's Dead Cat Bounce Stock - TheStreet.com
06/06/16 02:44 PMBLUEBIRD BIO INC. (NASDAQ:BLUE) Financial Condition Compared to S&P 500 - CML News
06/06/16 09:37 AMPerformance Review for bluebird bio, Inc. (NASDAQ:BLUE) - HNN
06/05/16 10:42 AMBluebird Bio, Inc. (NASDAQ:BLUE) Broker Price Targets For The Coming Week - Share Trading News
06/04/16 11:25 AMBluebird Bio, Inc. (NASDAQ:BLUE) Do Brokers Advise Buy, Sell Or Hold? - Share Trading News
06/03/16 08:59 PMbluebird bio, Inc. (NASDAQ:BLUE) up 5.21%: Inovio Pharmaceuticals, Inc. (NASDAQ:INO), HollySys Automation ... - KC Register
06/03/16 08:59 PMbluebird bio, Inc. (NASDAQ:BLUE) Stock Update & Estimates - Stock Tick Tock
06/03/16 11:26 AMStock To Watch: Bluebird Bio (BLUE) In Perilous Reversal - TheStreet.com
06/03/16 08:17 AMBLUEBIRD BIO, INC. Files SEC form 8-K, Submission of Matters to a Vote of Security Holders -
06/03/16 04:52 AMCoverage initiated on Bluebirdbio by Cantor Fitzgerald -
06/02/16 08:55 PMbluebird bio Inc (BLUE) Now Covered by Cantor Fitzgerald - Let Me Know About This - Risers & Fallersbluebird bio Inc (BLUE) Now Covered by Cantor FitzgeraldLet Me Know About Thisbluebird bio logo Equities research analysts at Cantor Fitzgerald began coverage on shares of bluebird bio Inc (NASDAQ:BLUE) in a report released on Thursday. The firm set a “hold” rating and a $42.00 price target on the stock. Cantor Fitzgerald's ...bluebird bio, Inc. (NASDAQ:BLUE) topped earnings-per-share estimates 8% of the timeZergwatchShares Of Bluebird Bio Inc (NASDAQ:BLUE) Rated As Hold By Analysts At Cantor FitzgeraldRisers & Fallersbluebird bio Inc (BLUE) Coverage Initiated by Analysts at Cantor FitzgeraldCommunity Financial NewsBenzinga -Equities Focus -The Postall 9 news articles »
06/02/16 08:55 PMbluebird bio Inc. (BLUE) Jumps 5.21% on June 02 - Equities.com - bluebird bio Inc. (BLUE) Jumps 5.21% on June 02Equities.combluebird bio Inc. (BLUE) was among the biggest gainers on the Russell 2000 for Thursday June 02 as the stock popped 5.21% to $47.87, representing a gain of $2.37 per share. Some 658,153 shares traded hands on 5,079 trades, compared with an average ...and more »
06/01/16 09:52 AMCelgene: Great Company, Great Innovation, Sorry About the Limited Upside -
05/31/16 02:56 PMbluebird bio, Inc. (NASDAQ:BLUE) Quarterly EPS Estimate At $-1.47 - Investor Newswire - bluebird bio, Inc. (NASDAQ:BLUE) Quarterly EPS Estimate At $-1.47Investor NewswireFirst Call stated that bluebird bio, Inc. (NASDAQ:BLUE) can touch $92.69 in coming one year. For the next quarter, the per-share earnings target is $-1.47 and for ongoing fiscal at $-5.88. EPS target for next year is $-5.97 versus the mean EPS of $-5 ...and more »
05/31/16 08:32 AMCostly gene therapies are coming, but how to pay for them? - The point, he added, is to cap drug costs. Orkin coauthored the essay with Dr. Philip Reilly of Third Rock Ventures, a Boston biotech investor that helped launch Voyager Therapeutics Inc. and bluebird bio Inc.. Both are gene therapy companies in Cambridge.
05/30/16 09:26 PMAre Analysts Bullish bluebird bio Inc (NASDAQ:BLUE) After Last Week? - HNN - Are Analysts Bullish bluebird bio Inc (NASDAQ:BLUE) After Last Week?HNNOut of 13 analysts covering bluebird bio (NASDAQ:BLUE), 12 rate it a “Buy”, 0 “Sell”, while 3 “Hold”. This means 80% are positive. bluebird bio has been the topic of 22 analyst reports since August 11, 2015 according to StockzIntelligence Inc. Below is ...Is it Time to Cash in Profits on bluebird bio, Inc. (NASDAQ:BLUE)Franklin IndependentNew Analyst Ratings On Bluebird Bio, Inc. (NASDAQ:BLUE)Risers & Fallersall 4 news articles »
05/30/16 09:26 PMAre Analysts Bullish bluebird bio Inc (NASDAQ:BLUE) After Last Week? - HNN - Are Analysts Bullish bluebird bio Inc (NASDAQ:BLUE) After Last Week?HNNOut of 13 analysts covering bluebird bio (NASDAQ:BLUE), 12 rate it a “Buy”, 0 “Sell”, while 3 “Hold”. This means 80% are positive. bluebird bio has been the topic of 22 analyst reports since August 11, 2015 according to StockzIntelligence Inc. Below is ...Is it Time to Cash in Profits on bluebird bio, Inc. (NASDAQ:BLUE)Franklin IndependentNew Analyst Ratings On Bluebird Bio, Inc. (NASDAQ:BLUE)Risers & Fallersall 4 news articles »
05/27/16 11:14 AMBluebird Bio, Inc. (NASDAQ:BLUE) Updated Broker Price Targets - Share Trading News - Bluebird Bio, Inc. (NASDAQ:BLUE) Updated Broker Price TargetsShare Trading NewsMarket analysts have recently updated their ratings and price targets on shares of bluebird bio, Inc. (NASDAQ:BLUE). The latest reports which are currently in issue on Thursday 26th of May state 0 analysts have a rating of “strong buy”, 0 analysts “buy ...and more »
05/27/16 11:14 AMTraders Actions to Focus: EXACT Sciences Corporation (NASDAQ:EXAS) , bluebird bio, Inc. (NASDAQ:BLUE) - Street Updates - Traders Actions to Focus: EXACT Sciences Corporation (NASDAQ:EXAS) , bluebird bio, Inc. (NASDAQ:BLUE)Street Updatesbluebird bio, Inc. (NASDAQ:BLUE) moved in red zone with decline of -0.72 points or -1.62% to $43.66. The company has a market worth of $1.61B.Total 728.98 thousand shares were exchanged in last trading session as opposed to average volume of 1.14 ...and more »
05/26/16 06:21 PMETF’s with exposure to bluebird bio, Inc. : May 26, 2016 -
About bluebird bio

bluebird bio logobluebird bio, Inc. is a clinical-stage biotechnology company. The Company is focused on developing and commercializing products based on the transformative potential of gene therapy to treat patients with severe genetic diseases and cancer. The Company's products include Lenti-D, LentiGlobin and CAR T Cells. The Company is developing Lenti-D to treat patients with CCALD (Childhood cerebral adrenoleukodystrophy), the severe form of ALD (Adrenoleukodystrophy). The Company is conducting a Phase II/III clinical study of Lenti-D in the United States. The Company is developing LentiGlobin to treat patients with b-thalassemia and severe SCD (sickle cell disease). The Company is conducting a Phase I/II clinical study of LentiGlobin. It also initiated a second Phase I/II clinical study in the United States, Australia and Thailand for LentiGlobin. The Company is developing CAR T cell technology to deliver T cells engineered to kill the cancer.

Industry, Sector and Symbol:
  • Sector: Healthcare
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: BLUE
  • CUSIP:
Key Metrics:
  • Previous Close: $39.72
  • 50 Day Moving Average: $41.77
  • 200 Day Moving Average: $47.26
  • P/E Ratio: N/A
  • P/E Growth: -0.03
  • Market Cap: $1.45B
  • Current Quarter EPS Consensus Estimate: $-5.89 EPS
Additional Links:
bluebird bio (NASDAQ:BLUE) Chart for Wednesday, June, 29, 2016


            As Featured by CNBC As Featured by The Wall Street Journal As Featured by MarketWatch As Featured by The Boston Globe As Featured by StockTwits As Featured by Seeking Alpha